138 related articles for article (PubMed ID: 18482668)
1. Clarithromycin attenuates acute and chronic rejection via matrix metalloproteinase suppression in murine cardiac transplantation.
Ogawa M; Suzuki J; Hishikari K; Takayama K; Tanaka H; Isobe M
J Am Coll Cardiol; 2008 May; 51(20):1977-85. PubMed ID: 18482668
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase suppression induced by clarithromycin in murine cardiac allografts.
Ogawa M; Suzuki J; Takayama K; Isobe M
Transplant Proc; 2009; 41(1):395-7. PubMed ID: 19249565
[TBL] [Abstract][Full Text] [Related]
3. Pioglitazone prevents acute and chronic cardiac allograft rejection.
Kosuge H; Haraguchi G; Koga N; Maejima Y; Suzuki J; Isobe M
Circulation; 2006 Jun; 113(22):2613-22. PubMed ID: 16735678
[TBL] [Abstract][Full Text] [Related]
4. Early treatment with clarithromycin attenuates rat autoimmune myocarditis via inhibition of matrix metalloproteinase activity.
Hishikari K; Watanabe R; Ogawa M; Suzuki J; Masumura M; Shimizu T; Takayama K; Hirata Y; Nagai R; Isobe M
Heart; 2010 Apr; 96(7):523-7. PubMed ID: 20350988
[TBL] [Abstract][Full Text] [Related]
5. Pitavastatin suppresses acute and chronic rejection in murine cardiac allografts.
Suzuki J; Koga N; Kosuge H; Ogawa M; Haraguchi G; Maejima Y; Saiki H; Isobe M
Transplantation; 2007 Apr; 83(8):1093-7. PubMed ID: 17452900
[TBL] [Abstract][Full Text] [Related]
6. Suppression of acute and chronic rejection by hepatocyte growth factor in a murine model of cardiac transplantation: induction of tolerance and prevention of cardiac allograft vasculopathy.
Yamaura K; Ito K; Tsukioka K; Wada Y; Makiuchi A; Sakaguchi M; Akashima T; Fujimori M; Sawa Y; Morishita R; Matsumoto K; Nakamura T; Suzuki J; Amano J; Isobe M
Circulation; 2004 Sep; 110(12):1650-7. PubMed ID: 15364799
[TBL] [Abstract][Full Text] [Related]
7. Suppression of acute and chronic cardiac allograft rejection in mice by inhibition of chemokine receptor 5 in combination with cyclosporine A.
Li J; Xia J; Zhang K; Xu L
J Surg Res; 2009 Nov; 157(1):81-90. PubMed ID: 19577762
[TBL] [Abstract][Full Text] [Related]
8. Clarithromycin attenuates myocardial ischemia-reperfusion injury.
Nakajima T; Hishikari K; Ogawa M; Watanabe R; Suzuki J; Nagashima A; Masumura M; Takayama K; Hirata Y; Nagai R; Isobe M
Expert Opin Ther Targets; 2010 Sep; 14(9):881-93. PubMed ID: 20662614
[TBL] [Abstract][Full Text] [Related]
9. Aberrant tubulointerstitial immunoexpression of matrix metalloproteinases MMP-2, MMP-9 and tissue inhibitor of matrix proteinase-2 (TIMP-2) in acute cellular rejection of human renal allograft.
Wagrowska-Danilewicz M; Danilewicz M
Pol J Pathol; 2008; 59(4):189-94. PubMed ID: 19391484
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of MMP-2/MMP-9 and potential benefit of an MMP inhibitor in experimental acute kidney allograft rejection.
Ermolli M; Schumacher M; Lods N; Hammoud M; Marti HP
Transpl Immunol; 2003; 11(2):137-45. PubMed ID: 12799196
[TBL] [Abstract][Full Text] [Related]
11. Decoy against nuclear factor-kappa B attenuates myocardial cell infiltration and arterial neointimal formation in murine cardiac allografts.
Suzuki J; Morishita R; Amano J; Kaneda Y; Isobe M
Gene Ther; 2000 Nov; 7(21):1847-52. PubMed ID: 11110417
[TBL] [Abstract][Full Text] [Related]
12. Clarithromycin suppresses the periodontal bacteria-accelerated abdominal aortic aneurysms in mice.
Aoyama N; Suzuki JI; Ogawa M; Watanabe R; Kobayashi N; Hanatani T; Yoshida A; Ashigaki N; Izumi Y; Isobe M
J Periodontal Res; 2012 Aug; 47(4):463-9. PubMed ID: 22181324
[TBL] [Abstract][Full Text] [Related]
13. Reduced intragraft mRNA expression of matrix metalloproteinases Mmp3, Mmp12, Mmp13 and Adam8, and diminished transplant arteriosclerosis in Ccr5-deficient mice.
Luckow B; Joergensen J; Chilla S; Li JP; Henger A; Kiss E; Wieczorek G; Roth L; Hartmann N; Hoffmann R; Kretzler M; Nelson PJ; Pérez de Lema G; Maier H; Wurst W; Balling R; Pfeffer K; Gröne HJ; Schlöndorff D; Zerwes HG
Eur J Immunol; 2004 Sep; 34(9):2568-78. PubMed ID: 15307189
[TBL] [Abstract][Full Text] [Related]
14. Evidence for recipient derived fibroblast recruitment and activation during the development of chronic cardiac allograft rejection.
Wu GD; Tuan TL; Bowdish ME; Jin YS; Starnes VA; Cramer DV; Barr ML
Transplantation; 2003 Aug; 76(3):609-14. PubMed ID: 12923453
[TBL] [Abstract][Full Text] [Related]
15. Tea catechins attenuate ventricular remodeling and graft arterial diseases in murine cardiac allografts.
Suzuki J; Ogawa M; Sagesaka YM; Isobe M
Cardiovasc Res; 2006 Jan; 69(1):272-9. PubMed ID: 16109389
[TBL] [Abstract][Full Text] [Related]
16. Catechins attenuate myocardial cell infiltration and fibrosis but do not prolong graft survival in murine cardiac allografts.
Suzuki J; Ogawa M; Sagesaka YM; Isobe M
Transplant Proc; 2005; 37(1):119-20. PubMed ID: 15808567
[TBL] [Abstract][Full Text] [Related]
17. Suppression of graft coronary artery disease by a brief treatment with a selective epsilonPKC activator and a deltaPKC inhibitor in murine cardiac allografts.
Tanaka M; Terry RD; Mokhtari GK; Inagaki K; Koyanagi T; Kofidis T; Mochly-Rosen D; Robbins RC
Circulation; 2004 Sep; 110(11 Suppl 1):II194-9. PubMed ID: 15364862
[TBL] [Abstract][Full Text] [Related]
18. Metalloproteinase inhibition has differential effects on alloimmunity, autoimmunity, and histopathology in the transplanted lung.
Yoshida S; Iwata T; Chiyo M; Smith GN; Foresman BH; Mickler EA; Heidler KM; Cummings OW; Fujisawa T; Brand DD; Baker A; Wilkes DS
Transplantation; 2007 Mar; 83(6):799-808. PubMed ID: 17414715
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulation by interleukin-4 suppresses matrix metalloproteinases and improves cardiac function in murine myocarditis.
Li J; Leschka S; Rutschow S; Schwimmbeck PL; Husmann L; Noutsias M; Westermann D; Poller W; Zeichhardt H; Klingel K; Tschope C; Schultheiss HP; Pauschinger M
Eur J Pharmacol; 2007 Jan; 554(1):60-8. PubMed ID: 17113076
[TBL] [Abstract][Full Text] [Related]
20. Increased activities of cardiac matrix metalloproteinases matrix metalloproteinase (MMP)-2 and MMP-9 are associated with mortality during the acute phase of experimental Trypanosoma cruzi infection.
Gutierrez FR; Lalu MM; Mariano FS; Milanezi CM; Cena J; Gerlach RF; Santos JE; Torres-Dueñas D; Cunha FQ; Schulz R; Silva JS
J Infect Dis; 2008 May; 197(10):1468-76. PubMed ID: 18444803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
